Publication & Citation Trends
Publications
0 total
Irreversible tyrosine kinase inhibition of epidermal growth factor receptor with afatinib in EGFR activating mutation-positive advanced non-small-cell lung cancer. OA
Cited by 19
Semantic Scholar
Breaking the biomarker code: PD-L1 expression and checkpoint inhibition in advanced NSCLC.
Cited by 34
Semantic Scholar
Thoracic irradiation in 3weeks for limited-stage small cell lung cancer: Is twice a day fractionation really needed?
Cited by 13
Semantic Scholar
New developments in the treatment of advanced squamous cell lung cancer: focus on afatinib
Cited by 1
Semantic Scholar
LUX-lung 3: A randomized, open-label, phase III study of afatinib vs pemetrexed and cisplatin as first-line treatment for patients with advanced adenocarcinoma of the lung harboring EGFR-activating mutations
Cited by 1
Semantic Scholar
Breast cancer, early stage OA
Cited by 44
Semantic Scholar
Acknowledgement to the Reviewers OA
Cited by 0
Semantic Scholar
Research Topics
Lung Cancer Treatments and Mutations
(202)
Lung Cancer Research Studies
(87)
Colorectal Cancer Treatments and Studies
(56)
Lung Cancer Diagnosis and Treatment
(54)
HER2/EGFR in Cancer Research
(34)
Affiliations
Ontario Institute for Cancer Research
Hershey (United States)
Fox Chase Cancer Center
BC Cancer Agency
Tri-Service General Hospital